2
Clinical Trials associated with Anti-CD19/CD22 chimeric antigen receptor T cell therapy(Nanjing Legend Biotech)Clinical study on the safety and efficacy of CD19/CD22 chimeric antigen receptor T cell cocktail combined with reinfusion in the treatment of refractory/relapsed acute B lymphocytic leukemia
Start Date01 Mar 2022 |
Sponsor / Collaborator- |
A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma
This is a prospective, single-arm, single-center, open-label, single-dose dose finding and expansion study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor efficacy profile of LCAR-L10D in subjects with CD19- and/or CD22-positive relapsed/refractory B-cell lymphoma after prior adequate standard of care.
100 Clinical Results associated with Anti-CD19/CD22 chimeric antigen receptor T cell therapy(Nanjing Legend Biotech)
100 Translational Medicine associated with Anti-CD19/CD22 chimeric antigen receptor T cell therapy(Nanjing Legend Biotech)
100 Patents (Medical) associated with Anti-CD19/CD22 chimeric antigen receptor T cell therapy(Nanjing Legend Biotech)
100 Deals associated with Anti-CD19/CD22 chimeric antigen receptor T cell therapy(Nanjing Legend Biotech)